newsfilter
← Latest News
GlobeNewswire·

Serina Therapeutics Provides Regulatory Update on SER-252 Program

- FDA requests additional information on a formulation component - HUNTSVILLE, AL, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing